Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Event: Senti Biosciences, Inc. (SNTI) filed a Form 4 reporting that director James J. Collins was granted 21,950 stock options on 06/25/2025.
Terms of the option: the exercise price is $2.05 per share, with 100 % of the underlying shares vesting on the earlier of (i) the first anniversary of the grant date or (ii) the company’s 2026 annual meeting, provided Mr. Collins remains in service until that date. The options expire on 06/24/2035.
Ownership impact: Following this grant, Collins directly holds 21,950 derivative securities (options) and no non-derivative transactions were reported. No shares were sold or otherwise disposed of in this filing.
Sign-off: The filing was executed by attorney-in-fact Timothy Lu and dated 06/27/2025.
Form 4 overview: On 06/25/2025, Senti Biosciences (ticker SNTI) reported granting director Feng Hsiung a stock option for 21,950 common shares at an exercise price of $2.05 per share.
The option, filed on 06/27/2025, vests 100 % on the earlier of (i) the first anniversary of the grant or (ii) the 2026 annual shareholders’ meeting, subject to continued board service. It carries a 10-year term with an expiration date of 06/24/2035.
No open-market purchase or sale of common shares occurred; the transaction is strictly an equity-based compensation award. After the grant, Mr. Hsiung beneficially owns 21,950 derivative securities, and the filing shows no change to his direct or indirect ownership of outstanding common shares. The disclosure does not reference a Rule 10b5-1 trading plan.
Investor take-away: This is a routine director compensation event that modestly aligns board incentives with shareholder value. It creates potential dilution only if exercised and has no immediate impact on cash flow, operations, or the company’s financial outlook. The Form 4 contains no earnings or operational data.
Senti Biosciences director Fran Schulz received a stock option grant on June 25, 2025. The grant consists of 21,950 options to purchase common stock at an exercise price of $2.05 per share.
Key terms of the option grant:
- Exercise price: $2.05 per share
- Expiration date: June 24, 2035
- Vesting schedule: 100% vests at earlier of (i) first anniversary of grant date or (ii) 2026 Annual Meeting
- Vesting contingent on continued service through applicable date
The Form 4 was filed by Robert Cutler as attorney-in-fact on June 27, 2025. This transaction represents standard non-employee director equity compensation and aligns the director's interests with shareholders through long-term stock ownership potential.
Form 4 Overview: On 06/27/2025 Senti Biosciences (ticker: SNTI) filed a Form 4 disclosing a routine equity award to board member Brenda Cooperstone. The report covers a single transaction dated 06/25/2025 and was signed by Timothy Lu as attorney-in-fact.
Key Transaction Details: The filing records the grant of 21,950 non-qualified stock options (Code A – grant) with an exercise price of $2.05 per share and an expiration date of 06/24/2035. Following the grant, Cooperstone beneficially owns exactly 21,950 derivative securities; no common shares or other derivative movements were reported in Table I.
Vesting Schedule: According to the footnote, 100% of the options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s 2026 Annual Meeting, contingent on the director’s continued service. Thus, full vesting is expected by mid-2026 at the latest.
Investor Implications: The event is part of standard director compensation and does not involve any open-market purchase or sale of existing shares. At 21,950 shares, the potential dilution is de-minimis relative to Senti’s total shares outstanding, and the strike price sits close to recent market levels, aligning incentives without materially affecting near-term cash flow or share count. No earnings, revenue data, or other operational disclosures accompany the filing.
Form 4 filing reveals that Donald F. Tang, Director at Senti Biosciences (SNTI), received a stock option grant on June 25, 2025. The derivative securities transaction details include:
- Granted 21,950 stock options to purchase common stock
- Exercise price set at $2.05 per share
- Options expire on June 24, 2035
- Vesting schedule: 100% vests at earlier of: - First anniversary of grant date - Date of 2026 Annual Meeting
Vesting is contingent on Tang's continued service through the applicable vesting date. The transaction was reported through an attorney-in-fact, Robert Cutler, on June 27, 2025. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.